Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease
Author:
Affiliation:
1. Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA; and
2. the Departments of Biostatistics,
3. Medicine, and
4. Pediatrics, University of Washington School of Medicine, Seattle, WA
Abstract
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Link
http://ashpublications.org/blood/article-pdf/121/12/2340/1364908/2340.pdf
Reference34 articles.
1. Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease.;Flowers;Biol Blood Marrow Transplant,2008
2. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.;Wolff;Biol Blood Marrow Transplant,2011
3. A survey of diagnosis, management, and grading of chronic GVHD.;Lee;Biol Blood Marrow Transplant,2002
4. Individual physician practice variation in hematopoietic cell transplantation.;Lee;J Clin Oncol,2008
5. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.;Martin;Biol Blood Marrow Transplant,2006
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Long-Term Experience in a Multi-Centre Study for Adult and Pediatric Patients, on Behalf of GETH-TC;2024-07-22
2. An open‐label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid‐dependent/steroid‐resistant chronic GVHD;American Journal of Hematology;2024-06-27
3. The Importance of Treatment Response for Outcome of Patients With Chronic Graft-Versus-Host Disease;Transplantation and Cellular Therapy;2024-06
4. Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study;Bone Marrow Transplantation;2024-05-02
5. Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development;Current Oncology;2024-03-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3